In the present study, we first conducted a retrospective study to evaluate the prognostic value of STK11 in a FFPE specimen cohort, second explored the prognostic differences between wild-type and mutated STK11 NSCLC patients through TCGA databases, then third compared the differentially expressed genes related to immunotherapy between the two subtypes of patients via bioinformatic analyses. The gene discussed is STK11; the disease is non-small cell lung carcinoma.